Carbylan Therapeutics, Inc.

As of November 21, 2016, Carbylan Therapeutics, Inc. was acquired by KalVista Pharmaceuticals, Inc., in a reverse merger transaction. Carbylan Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of novel and proprietary combination therapies. Its product candidate is Hydros-TA, which is in Phase III clinical trial designed to provide rapid and sustained relief from pain associated with osteoarthritis. The company was formerly known as Carbylan Biosurgery, Inc. and changed its name to Carbylan Therapeutics, Inc. in March 2014. Carbylan BioSurgery, Inc. was founded in 2004 and is headquartered in Palo Alto, California.